Life sciences cases tracker—EU

Copyright © 2025 LexisNexis
Published by a LexisNexis Life Sciences expert
Practice notes

Life sciences cases tracker—EU

Copyright © 2025 LexisNexis

Published by a LexisNexis Life Sciences expert

Practice notes
imgtext

This Practice Note is intended to be used to track the progress of EU cases relevant to the life sciences sector.

Jump to:

  1. •

    Judgments—Supplementary protection certificates

  2. •

    Judgments—Medical devices and medicinal products

  3. •

    Judgments—Access to documents

  4. •

    Judgments—EPO Enlarged Board of Appeal

  5. •

    Judgments—Unified Patent Court (UPC)

  6. •

    Judgments—Trade marks

For archived items on life sciences, see Practice Note: Life sciences tracker [Archived].

Judgments—Supplementary protection certificates

For archived supplementary protection certificate (SPCs) judgments, see Practice Note: Life sciences tracker [Archived]—Judgments—Supplementary protection certificates.

Court of Justice of the European Union

What's happening?When?Find out more
Supreme Court of Ireland judgment in Merck Sharp & Dohme v Clonmel Healthcare Ltd
S:AP:IE:2021:000052 [2022] IESC 11		21 February 2022: Referral to the Court of Justice.Referral to the Court of Justice—SPCs
The Supreme Court of Ireland has requested a ruling from the Court of Justice on the following questions:
—for the purpose of the grant of an SPC, and for the validity of that SPC in law, under Article 3(a) of Regulation (EC) 469/2009 (the SPC Regulation),
Powered by Lexis+®
Jurisdiction(s):
United Kingdom
Key definition:
Marketing Authorisation definition
What does Marketing Authorisation mean?

The approval needed to place a medicinal product on the market. It sets out the medical conditions (known as indications), patient population and dosage for which the product is authorised as well as any conditions imposed on the holder of the marketing authorisation.

Read more

Popular documents

Micklefield clauses

Micklefield clausesWhat is a Micklefield clause?It is common for employee share plans to provide that, on termination of employment (or when an employee is given or receives notice of termination of employment), subsisting share awards will be forfeited and subsisting share options will lapse.It is

Early leavers—preservation

Early leavers—preservationFORTHCOMING DEVELOPMENT: Section 10 of the Finance Act 2022 will increase the normal minimum pension age (NMPA) from 55 to 57 on 6 April 2028 (save for members of the firefighters, police and armed forces public service pension schemes).The Finance Act 2022 will also give

Brussels I (recast)—domicile (Arts 4 and 63) [Archived]

Brussels I (recast)—domicile (Arts 4 and 63) [Archived]ARCHIVED: This Practice Note has been archived and is not maintained.This Practice Note considers the general rule set out in Article 4 of Regulation (EU) 1215/2012, Brussels I (recast) when determining the relevance of a defendant’s domicile to

Where are misrepresentations made? Jurisdictional traps for the unwary (Bellmare Holdings Ltd v Wells)

Dispute Resolution analysis: The High Court has provided concise guidance as to how misrepresentation should be analysed when considering jurisdictional gateways. Under Article 5(3) of the Lugano Convention, in negligent misstatement cases, the place of the event giving rise to damage is normally